Slowing growth in emerging markets hits Nurofen maker Reckitt Benckiser as it misses sales expectations
Slowing growth in emerging markets hit consumer goods giant Reckitt Benckiser as it missed sales expectations.
The Durex and Nurofen maker reported like for like growth of 2 per cent in the third quarter.
Once its pharmaceuticals arm RB Pharmaceuticals, which the company is in the process of spinning off, is stripped out, sales rose by 3 per cent.
Slowing growth: The maker of Neurofen was impacted as warmer weather in Europe and the US saw fewer people stocking up on cold remedies
By this is still shy of the 3.7 per cent that analysts had expected.
The division, which analysts value at up to £2.5bn, will be sold by the end of the year, it said.
Reckitt also warned that the annual sales growth will be at the lower end of the company’s range, which is between 4 per cent and 5 per cent, amid slowing markets in southeast Asia and Latin America.
Total revenues for the quarter were £2.37bn, lower than the £2.43bn analysts had expected.
Consumer goods giants have been hit by stalling growth in emerging markets.
A quarter of Reckitt’s sales come from Asia Pacific and Latin America, and the group has been affected by Brazil’s slowing growth.
Chief executive Rakesh Kapoor said: ‘Looking ahead, our objective remains to deliver growth which outperforms our markets, although conditions will remain challenging.
'I continue to expect that the strength of our brands and the quality of our innovations will deliver our full year revenue targets.’
Jefferies analyst Martin Deboo said: ‘The market will view this as a modest disappointment. They’re being hurt by Brazil. That’s more of a market issue than a Reckitt-specific issue.’
Shares slipped 105p to 5010p.
Most watched Money videos
- BMW meets Swarovski and releases BMW i7 Crystal Headlights Iconic Glow
- How to invest for income and growth: SAINTS' James Dow
- 'Now even better': Nissan Qashqai gets a facelift for 2024 version
- Tesla unveils new Model 3 Performance - it's the fastest ever!
- Mercedes has finally unveiled its new electric G-Class
- Mini celebrates the release of brand new all-electric car Mini Aceman
- MailOnline asks Lexie Limitless 5 quick fire EV road trip questions
- 2025 Aston Martin DBX707: More luxury but comes with a higher price
- Land Rover unveil newest all-electric Range Rover SUV
- Leapmotor T03 is set to become Britain's cheapest EV from 2025
- Blue Whale fund manager on the best of the Magnificent 7
- Mail Online takes a tour of Gatwick's modern EV charging station
- RUTH SUNDERLAND: Stop cynical Royal Mail bid
- AstraZeneca to construct $1.5bn cancer drugs facility in...
- Ryanair profits soar to record high of almost €2bn
- Revealed: The investments that will really make a holiday...
- Top industrialist Sir Jim Ratcliffe blames high taxes for...
- Australian miner looking to buy Anglo American set to...
- Cadbury owner Mondelez to face scrutiny over selling...
- I was 'brokefished' by my friend for £400 - can I salvage...
- Where it REALLY pays to own a holiday let - how to turn a...
- British Land sells stake in Sheffield's Meadowhall...
- BUSINESS LIVE: Ryanair profits soar; AstraZeneca builds...
- Who would qualify for a £100 Nationwide loyalty bonus...
- Britain's new bonkers EV: Callum Skye is an £80k electric...
- CITY WHISPERS: Boss Cook-ing up a big sparkler to woo De...
- St James's Place facing humiliating exit from FTSE 100
- Sales at Bloomsbury soar thanks to the craze for...
- Revealed: The seven pensions savings habits that could...
- How to invest in the Ozempic weight loss boom - and pile...